US Edition
Cadila Pharmaceuticals Launches Biscado (Bisoprolol) for Cardiovascular Disease Management in India - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Cadila Pharmaceuticals launches Biscado (Bisoprolol) for cardiovascular disease management in India - Express Pharma
Cadila Pharmaceuticals has announced the launch of Biscado (Bisoprolol), marking its entry into the beta-blocker therapy segment used for managing cardiovascular diseases in India. Bisoprolol is a beta-1 adrenergic blocker indicated for the treatment of high blood pressure, angina, and chronic heart failure. The drug works by reducing heart rate and blood pressure, helping to reduce strain on the heart. It is used to improve survival and reduce …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
